niacinamide has been researched along with Familial Nonmedullary Thyroid Cancer in 11 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma." | 9.15 | Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 7.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 7.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma." | 5.15 | Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 3.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| "THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)." | 3.80 | Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 3.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and platelet-derived growth factor receptor β)." | 2.49 | Sorafenib and thyroid cancer. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S, 2013) |
| "Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection." | 1.48 | Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. ( Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB, 2018) |
| "Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity." | 1.40 | Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. ( Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK, 2014) |
| "Here we present a man with pancreatic metastases from PTC, report our experience with sorafenib therapy, and discuss the role of endoscopic ultrasound (EUS)-guided biopsy in its diagnosis." | 1.38 | Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012) |
| "Patients with progressive refractory thyroid cancer are potential candidates for clinical trials using tyrosine kinase inhibitors (TKIs), and a promising proportion of patients in these trials have achieved stable disease." | 1.37 | Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. ( Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danilovic, DLS | 1 |
| Castro, G | 1 |
| Roitberg, FSR | 1 |
| Vanderlei, FAB | 1 |
| Bonani, FA | 1 |
| Freitas, RMC | 1 |
| Coura-Filho, GB | 1 |
| Camargo, RY | 1 |
| Kulcsar, MA | 1 |
| Marui, S | 1 |
| Hoff, AO | 1 |
| Iyer, P | 1 |
| Mayer, JL | 1 |
| Ewig, JM | 1 |
| Shawa, H | 1 |
| Busaidy, NL | 2 |
| Schellingerhout, D | 1 |
| Habra, MA | 2 |
| Fallahi, P | 1 |
| Ferrari, SM | 1 |
| Santini, F | 1 |
| Corrado, A | 1 |
| Materazzi, G | 1 |
| Ulisse, S | 1 |
| Miccoli, P | 1 |
| Antonelli, A | 1 |
| Massicotte, MH | 1 |
| Brassard, M | 1 |
| Claude-Desroches, M | 1 |
| Borget, I | 1 |
| Bonichon, F | 1 |
| Giraudet, AL | 1 |
| Do Cao, C | 1 |
| Chougnet, CN | 1 |
| Leboulleux, S | 1 |
| Baudin, E | 1 |
| Schlumberger, M | 1 |
| de la Fouchardière, C | 1 |
| Dadu, R | 1 |
| Waguespack, SG | 1 |
| Sherman, SI | 1 |
| Hu, MI | 1 |
| Jimenez, C | 1 |
| Ying, AK | 1 |
| Bassett, RL | 1 |
| Cabanillas, ME | 1 |
| Chen, L | 1 |
| Shen, Y | 1 |
| Luo, Q | 1 |
| Yu, Y | 1 |
| Lu, H | 1 |
| Zhu, R | 1 |
| Toubert, ME | 1 |
| Vercellino, L | 1 |
| Faugeron, I | 1 |
| Lussato, D | 1 |
| Hindie, E | 1 |
| Bousquet, G | 1 |
| Alzahrani, AS | 1 |
| AlQaraawi, A | 1 |
| Al Sohaibani, F | 1 |
| Almanea, H | 1 |
| Abalkhail, H | 1 |
| Matsuse, M | 1 |
| Mitsutake, N | 1 |
| Tanimura, S | 1 |
| Ogi, T | 1 |
| Nishihara, E | 1 |
| Hirokawa, M | 1 |
| Fuziwara, CS | 1 |
| Saenko, VA | 1 |
| Suzuki, K | 1 |
| Miyauchi, A | 1 |
| Yamashita, S | 1 |
| Cohen, SM | 1 |
| Mukerji, R | 1 |
| Timmermann, BN | 1 |
| Samadi, AK | 1 |
| Cohen, MS | 1 |
1 review available for niacinamide and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carci | 2013 |
1 trial available for niacinamide and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disea | 2011 |
9 other studies available for niacinamide and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy | 2018 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; | 2014 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Dis | 2014 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outco | 2011 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Ou | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cel | 2013 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papill | 2012 |